Joint Action Antimicrobial Resistance and Healthcare-Associated Infections 2

Antimicrobial resistance (AMR), particularly antibiotic resistance, has arisen as a serious cross-border threat to health with the
potential to undermine modern medicine. In the EU, antibiotic resistance accounts for at least 33,000 deaths, 2.5 million extra
hospital days, and an estimated societal cost of about €1.5 billion each year. To combat AMR, a global approach is called for,
combining awareness raising, surveillance, antimicrobial stewardship (AMS), infection prevention/control (IPC) while ensuring access
to antibiotics and diagnostics. Such interventions need to be grounded in a One Health perspective, considering the interconnection
between humans, animals and the environment. Following the 2017 EU One Health Action Plan against AMR to make Europe a best
practice region and the first European Joint Action (JA) on AMR and Healthcare-Associated Infections (EU-JAMRAI), this new JA, EUJAMRAI 2, will support Member States/Associated Countries (MS/AC) in their efforts to develop and update their National Action Plan
(NAP) on AMR.